Treatment of osteopenia and osteoprossis in children

Comparisson of effectivness of parentral pamidronate And oral Alendronate for treatment osteoprossis and osteopenia in pediatric rheumatoid diseases

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211121053122N1

Enrollment

Registered

2022-03-04

Start date

2021-11-30

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteopenia.osteoprossis. Osteopetrosis

Interventions

Intervention 1: Intervention Group 1: In all patients, bone densitometic measurement is performed as soon as systemic rheumatic disease is diagnosed, and patients diagnosed with osteoporosis and osteo

Eligibility

Sex/Gender

All

Age

3 Years to 18 Years

Inclusion criteria

Inclusion criteria: Rheumatic disease- No hypocalcemia Age 3-18 year

Exclusion criteria

Exclusion criteria: Hypercalciuria Metabolic disease

Design outcomes

Primary

Measure	Time frame
Bone mineral Density. Timepoint: 6 month. Method of measurement: Bone Mineral Densitometry with DEXA method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Jari

Esfahan University of Medical Sciences

Mjari14@yahoo.com00o8 0

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026